Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update

Diabetes mellitus (DM) and heart failure (HF) are two chronic disorders that affect millions worldwide. Hyperglycemia can induce excessive generation of highly reactive free radicals that promote oxidative stress and further exacerbate diabetes progression and its complications. Vascular dysfunction...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-08, Vol.11 (16), p.4660
Main Authors: Koniari, Ioanna, Velissaris, Dimitrios, Kounis, Nicholas G, Koufou, Eleni, Artopoulou, Eleni, de Gregorio, Cesare, Mplani, Virginia, Paraskevas, Themistoklis, Tsigkas, Grigorios, Hung, Ming-Yow, Plotas, Panagiotis, Lambadiari, Vaia, Ikonomidis, Ignatios
Format: Article
Language:English
Subjects:
Antidiabetics
Clinical medicine
GLP-1 receptor agonists
Insulin resistance
Kinases
Mortality
Oxidation
Oxidative stress
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes mellitus (DM) and heart failure (HF) are two chronic disorders that affect millions worldwide. Hyperglycemia can induce excessive generation of highly reactive free radicals that promote oxidative stress and further exacerbate diabetes progression and its complications. Vascular dysfunction and damage to cellular proteins, membrane lipids and nucleic acids can stem from overproduction and/or insufficient removal of free radicals. The aim of this article is to review the literature regarding the use of antidiabetic drugs and their role in glycemic control in patients with heart failure and oxidative stress. Metformin exerts a minor benefit to these patients. Thiazolidinediones are not recommended in diabetic patients, as they increase the risk of HF. There is a lack of robust evidence on the use of meglinitides and acarbose. Insulin and dipeptidyl peptidase-4 (DPP-4) inhibitors may have a neutral cardiovascular effect on diabetic patients. The majority of current research focuses on sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. SGLT2 inhibitors induce positive cardiovascular effects in diabetic patients, leading to a reduction in cardiovascular mortality and HF hospitalization. GLP-1 receptor agonists may also be used in HF patients, but in the case of chronic kidney disease, SLGT2 inhibitors should be preferred.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11164660